# Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

> **NCT03156842** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 138 (actual)

## Conditions studied

- Essential Hypertension
- Dyslipidemia

## Interventions

- **DRUG:** Fimasartan/Amlodipine, Rosuvastatin
- **DRUG:** Fimasartan/Amlodipine
- **DRUG:** Fimasartan, Rosuvastatin

## Key facts

- **NCT ID:** NCT03156842
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-29
- **Primary completion:** 2018-12-07
- **Final completion:** 2018-12-07
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03156842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03156842, "Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03156842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*